CLL/SLL
Haematology · 2015–2024
7decisions
3medicines
7carried consumer input
92individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ibrutinib Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), in combination with venetoclax, for patients suitable for… | Mar 2024 | Recommended | 64 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| zanubrutinib Relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) considered unsuitable for treatment or retreatment with a purine… | Mar 2023 | Recommended | 1 individuals Haematology Society · Rare Cancers Australia · Lymphoma Australia |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are unsuitable for… | Nov 2021 | Not recommended | input received Rare Cancers Australia · Leukaemia Foundation |
| acalabrutinib Treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients considered unsuitable for treatment with… | Jul 2020 | Not recommended | 13 individuals |
| ibrutinib Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that is relapsed or refractory to at least one prior therapy, and mantle cell lymphoma… | Nov 2020 | Recommended | input received Leukaemia Foundation |
| ibrutinib Two conditions: (1) relapsed or refractory mantle cell lymphoma; (2) first-line treatment of patients with chronic lymphocytic leukaemia or small lymphocytic… | Mar 2018 | Recommended with restriction | 2 individuals |
| ibrutinib Second-line treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in patients unsuitable for purine… | Nov 2015 | Deferred | 12 individuals |
Who spoke
Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia · Haematology Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.